RESEARCH PAPER
Alteration in diurnal and nocturnal melatonin serum level in patients with chronic heart failure
 
More details
Hide details
1
Department of Internal Diseases, Medical University, Lublin, Poland
2
Department of Laboratory Diagnostics, Medical University, Lublin, Poland
3
Department of Family Medicine, Medical University, Lublin, Poland
CORRESPONDING AUTHOR
Grzegorz Dzida   

Department of Internal Diseases, Medical University, Lublin, Poland
 
Ann Agric Environ Med. 2013;20(4):745–748
KEYWORDS
ABSTRACT
Introduction:
Melatonin is best known for its influence on circardian physiology. The circulating levels of the hormone vary in a daily cycle, allowing the regulation of the circadian rhythms of several biological functions. Melatonin is now considered as a cardioprotective factor and its secretion might be influenced by the clinical course of CHF.

Objective:
Assessment of the alteration in diurnal and nocturnal melatonin serum levels in patients with chronic heart failure.

Material and Methods:
The study group consisted of 32 patients diagnosed with CHF according to ESC criteria. The study group was divided into two subgroups: patients in NYHA class II (n=21, 8 women) and patients in NYHA class III (n=11, 6 women). In all patients, serum melatonin levels at 02:00 and at 07:00 were determined using competitive enzyme immunoassay technique. High-sensitive C-reactive protein (HsCRP) was determined with nephelometric method.

Results:
Mean hsCRP level was 0.368 (0.195; 0.794) mg/l and 0.54 (0.128; 1.04) mg/l in the group NYHA II and NYHA III patients, respectively; the difference was not statistically significant. NTproBNP levels were higher in NYHA III group than in the group NYHA II [2300 (1509;6317) pg/ml vs 7157 (4155; 13339) pg/ml]; the difference was substantial and approached the level of statistical significance (p=0.057). In both subgroups, higher levels of melatonin at 02:00 than at 07:00 was noticed; however, the differences were not statistically significant (p>0.05). In NYHA III subgroup lower levels of melatonin were observed at both time points; the difference was not statistically significant.

 
REFERENCES (26)
1.
Berry C, Murdoch D, McMurray J. Economics of chronic heart failure. Eur J Heart Fail. 2001; 3(3): 283–291.
 
2.
Komajda M, Pousset F, Isnard R, Lechat P. The role of the neurohormonal system in heart. Heart 1998; 79(Suppl 2): 17–23.
 
3.
Zhdanova IV, Tucci V. Melatonin, circadian rhythms, and sleep. Curr Treat Options Neurol. 2003; 5(3): 225–229.
 
4.
Buscemi N, Vandermeer B, Pandya R, Hooton N, Tjosvold L, Hartling L, et al. Melatonin for treatment of sleep disorders. Evid Rep Technol Assess. 2004; 108: 1–7.
 
5.
Koziróg M, Poliwczak AR, Duchnowicz P, Koter-Michalak M, Sikora J, Broncel M. Melatonin treatment improves blood pressure, lipid profile, and parameters of oxidative stress in patients with metabolic syndrome. J Pineal Res. 2011; 50(3): 261–266.
 
6.
Duncker DJ, Verdouw PD. Has Melatonin a Future as a Cardioprotective Agent? Cardiovasc Drugs Ther. 2001; 15: 205–207.
 
7.
Patel V, Upaganlawar A, Zalawadia R, Balaraman R. Cardioprotective effect of melatonin against isoproterenol induced myocardial infarction in rats: A biochemical, electrocardiographic and histoarchitectural evaluation. Eur J Pharmacol. 2010; 644(1–3): 160–168.
 
8.
Mukherjee R, Banerjee S, Joshi N, Singh PK, Baxi D, Ramachandran AV. A combination of melatonin and alpha lipoic acid has greater cardioprotective effect than either of them singly against cadmiuminduced oxidative damage. Cardiovasc Toxicol. 2011; 11(1): 78–88.
 
9.
Ekmekcioglu C, Haslmayer P, Philipp C, Mehrabi MR, Glogar HD, Grimm M, et al. Expression of the MT1 melatonin receptor subtype in human coronary arteries. J Recept Signal Transduct Res. 2001; 21(1): 85–91.
 
10.
Ekmekcioglu C, Thalhammer T, Humpeler S, Mehrabi MR, Glogar HD, Hölzenbein T, et al. The melatonin receptor subtype MT2 is present in the human cardiovascular system. J Pineal Res. 2003; 35(1): 40–44.
 
11.
Tan DX, Chen LD, Poegeller B, Manchester LC, Reiter RJ. Melatonin: a potent,endogenous hydroxyl radical scavenger. Endocr J. 1993; 1: 57–60.
 
12.
Scheer FA, Van Montfrans GA, Van Someren EJ, Mairuhu G, Buijs RM. Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension. Hypertension. 2004; 43: 192–197.
 
13.
Arangino S, Cagnacci A, Angiolucci M, Vacca AM, Longu G, Volpe A, et al. Effects of melatonin on vascular reactivity, catecholamine levels and blood pressure in healthy men. Am J Cardiol. 1999; 83: 1417–1419.
 
14.
Salie R, Harper I, Cillie C, Genade S, Huisamen B, Moolman J, et al. Melatonin protects against ischaemic-reperfusion myocardial damage. J Mol Cell Cardiol. 2001; 33: 343–357. 15. Oz E, Ilhan MN. Effects of melatonin in reducing the toxic effects of doxorubicin. Mol Cell Biochem. 2006; 286(1–2): 11–5.
 
15.
Reiter RJ, Manchester LC, Fuentes-Broto L, Tan DX. Cardiac hypertrophy and remodelling: pathophysiological consequences and protective effects of melatonin. J Hypertens. 2010; 28(Suppl 1): 7–12.
 
16.
Stehle JH, Foulkes NS, Molina CA, Simonneaux V, Pévet P, SassoneCorsi P. Adrenergic signals direct rhythmic expression of transcriptional repressor CREM in the pineal gland. Nature 1993; 365: 314–320.
 
17.
Girotti L, Lago M, Ianovsky O, Elizari MV, Dini A, Lloret SP, et al. Low Urinary 6-Sulfatoxymelatonin Levels in Patients with Severe Congestive Heart Failure. Endocrine. 2003; 22(3): 245–248.
 
18.
Arzt M, Young T, Finn L, Skatrud JB, Ryan CM, Newton GE, et al. Sleepiness and sleep in patients with both systolic heart failure and obstructive sleep apnea. Arch Intern Med. 2006; 166: 1716–1722.
 
19.
Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002; 347: 161–167.
 
20.
Stanek B, Frey B, Hülsmann M, Berger R, Sturm B, Strametz-Juranek J, et al. Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. J Am Coll Cardiol. 2001; 38: 436–442.
 
21.
Hammond HK. Mechanisms of myocardial beta-adrenergic receptor desensitization in heart failure. Circulation. 1993; 87: 454–63.
 
22.
Kaye DM, Lambert GW, Lefkovits J, Morris M, Jennings G, Esler MD. Neurochemical evidence of cardiac sympathetic activation and increased central nervous system norepinephrine turnover in severe congestive heart failure. J Am Coll Cardiol. 1994; 23: 570–578.
 
23.
Levine B, Kalman J, Mayer L, Fillit H, Packer M. Elevated circulating levels of tumor necrosis factor in congestive heart failure. N Engl. J Med. 1990; 323: 236–241.
 
24.
Brunetti ND, Troccoli R, Correale M, Pellegrino PL, Di Biase M. Creative protein in patients with acute coronary syndrome: correlation with diagnosis, myocardial damage, ejection fraction and angiographic findings. Int J Cardiol. 2006; 109(2): 248–256.
 
25.
Dominguez-Rodriguez A, Garcia-Gonzalez M, Abreu-Gonzalez P, Ferrer J, Kaski JC. Relation of nocturnal melatonin levels to c-reactive protein concentration in patients with ST-segment elevation myocardial infarction. Am J Cardiol. 2006; 97: 10–12.
 
26.
Dominguez-Rodriguez A, Kaski JC, Abreu-Gonzalez P, GarciaGonzalez M. Cross-talk between C-reactive protein and light/dark variations. Int J Cardiol. 2007; 120(1): 130.
 
eISSN:1898-2263
ISSN:1232-1966